Inovio Pharmaceuticals Inc Cash Flow Conversion Efficiency
Inovio Pharmaceuticals Inc cash flow conversion efficiency. Based on the latest financial reports, Inovio Pharmaceuticals Inc (INO) has a cash flow conversion efficiency ratio of 2.795x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-21.57 Million) by net assets ($-7.72 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Inovio Pharmaceuticals Inc (1998–2024)
Cash flow conversion efficiency of Inovio Pharmaceuticals Inc from 1998 to 2024. This chart illustrates how Inovio Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View INO share price today for real-time trading data and today's change.
Inovio Pharmaceuticals Inc Cash Flow Conversion Ratio Explained
Inovio Pharmaceuticals Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Inovio Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Inovio Pharmaceuticals Inc ranked by their cash flow conversion efficiency. Also see Inovio Pharmaceuticals Inc (INO) market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Shimmick Corporation Common Stock
NASDAQ:SHIM
|
0.340x |
|
Optical Cable Corporation
NASDAQ:OCC
|
0.062x |
|
Vita Life Sciences Ltd
AU:VLS
|
0.125x |
|
Yen Sun Technology
TWO:6275
|
0.026x |
|
Faraday Future Intelligent Electric Inc
NASDAQ:FFIE
|
-0.389x |
|
Shin Foong Specialty and Applied Materials Co
TW:6582
|
-0.001x |
|
Bms Birlesik Metal Sanayi ve Ticaret AS
IS:BMSTL
|
0.040x |
|
Lastminute.com NV
SW:LMN
|
1.485x |
Annual Cash Flow Conversion Efficiency for Inovio Pharmaceuticals Inc (1998–2024)
The table below shows the annual cash flow conversion efficiency of Inovio Pharmaceuticals Inc from 1998 to 2024. Review how much free cash does Inovio Pharmaceuticals Inc generate to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $68.50 Million | $-104.08 Million | -1.519x | -43.36% |
| 2023-12-31 | $117.35 Million | $-124.37 Million | -1.060x | -8.99% |
| 2022-12-31 | $222.36 Million | $-216.22 Million | -0.972x | -80.16% |
| 2021-12-31 | $399.67 Million | $-215.71 Million | -0.540x | -39.84% |
| 2020-12-31 | $461.14 Million | $-177.98 Million | -0.386x | +97.87% |
| 2019-12-31 | $5.40 Million | $-97.85 Million | -18.104x | -2042.27% |
| 2018-12-31 | $87.03 Million | $-73.55 Million | -0.845x | -90.50% |
| 2017-12-31 | $142.49 Million | $-63.21 Million | -0.444x | +12.51% |
| 2016-12-31 | $123.38 Million | $-62.56 Million | -0.507x | -617.11% |
| 2015-12-31 | $175.93 Million | $-12.44 Million | -0.071x | +73.56% |
| 2014-12-31 | $111.54 Million | $-29.82 Million | -0.267x | +8.04% |
| 2013-12-31 | $52.90 Million | $-15.38 Million | -0.291x | +54.57% |
| 2012-12-31 | $34.86 Million | $-22.31 Million | -0.640x | -55.04% |
| 2011-12-31 | $47.86 Million | $-19.76 Million | -0.413x | -62.86% |
| 2010-12-31 | $47.10 Million | $-11.94 Million | -0.253x | -10.13% |
| 2009-12-31 | $61.18 Million | $-14.08 Million | -0.230x | +60.48% |
| 2008-12-31 | $19.11 Million | $-11.13 Million | -0.582x | -56.97% |
| 2007-12-31 | $31.03 Million | $-11.51 Million | -0.371x | -23.80% |
| 2006-12-31 | $23.50 Million | $-7.04 Million | -0.300x | +42.99% |
| 2005-12-31 | $23.47 Million | $-12.34 Million | -0.526x | -20.20% |
| 2004-12-31 | $15.55 Million | $-6.80 Million | -0.437x | -139.45% |
| 2003-12-31 | $15.05 Million | $-2.75 Million | -0.183x | +86.28% |
| 2002-12-31 | $3.73 Million | $-4.96 Million | -1.331x | +21.06% |
| 2001-12-31 | $4.96 Million | $-8.37 Million | -1.687x | -89.75% |
| 2000-12-31 | $9.89 Million | $-8.79 Million | -0.889x | -66.92% |
| 1999-12-31 | $11.83 Million | $-6.30 Million | -0.532x | +29.85% |
| 1998-12-31 | $8.30 Million | $-6.30 Million | -0.759x | -- |
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA s… Read more